Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230405 | PMC |
| http://dx.doi.org/10.3324/haematol.2022.282025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological Features, Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase (ALK) Rearrangement-Based Survival of Patients With Advanced Non-small Cell Lung Cancer in a Tertiary Care Setting.
Cureus
December 2024
Clinical Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Background Lung cancer is the most frequent cause of cancer-related deaths and the most common type of cancer globally. It is generally classified into two main histologic subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most prevalent type and is enriched with genetic and molecular diversity.
View Article and Find Full Text PDFSystemic ALK-negative anaplastic large cell lymphoma: Insights into morphologic, immunophenotypic, genetic and molecular characteristics.
Hum Pathol
October 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. Electronic address:
Anaplastic large cell lymphoma (ALCL) is a mature T-cell neoplasm characterized by large pleomorphic cells, often with horseshoe- or kidney-shaped nuclei and abundant cytoplasm (hallmark cells), and uniformly strong CD30 expression. Based on ALK expression or ALK rearrangement, ALCL is further classified into ALK-positive (ALK+) and ALK-negative types. This review focuses on the clinicopathologic, immunophenotypic, cytogenetic and molecular features of systemic ALK-negative ALCL.
View Article and Find Full Text PDFRegistry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.
JCO Glob Oncol
September 2024
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Purpose: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis.
Materials And Methods: We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor () mutations or anaplastic large-cell lymphoma kinase () rearrangement-positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) -negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment.
Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement.
J Hematop
December 2024
Department of Pathology, University of Colorado Hospital, University of Colorado School of Medicine, 12605 East 16 Avenue, Aurora, CO, 80045, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma, primarily characterized by ALK gene rearrangements, though about 20-50% are ALK negative (ALK- ALCL) and display different genetic changes.
- A unique case of systemic ALK- ALCL involved a genetic fusion (NPM1::TYK2) that complicated diagnosis until next-generation sequencing (NGS) was applied.
- The NGS results revealed clonal rearrangement and a previously unreported NPM1::TYK2 fusion in systemic ALK- ALCL, highlighting its significance and rarity in comparison to other lymphoid conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!